VAX014 Co-Delivers STING/RIG-I Agonists with a Novel Oncolytic Mechanism to Facilitate Robust in situ Immunization Prior to Systemic Checkpoint Blockade
Time: 4:30 pm
day: Day One
Details:
• How VAX014, a novel tumor-targeted oncolytic agent based on recombinant bacterial minicells can facilitate in situ immunization
• Nonclinical data to support VAX014's ability to function optimally in STING/RIG-I positive tumors
• Nonclinical data to show that VAX014 in combination with immune checkpoint inhibitors gives additive benefit in the treatment of solid tumors
